Oregon Public Employees Retirement Fund Arcus Biosciences, Inc. Transaction History

Oregon Public Employees Retirement Fund

  • $5.14 Billion
  • Q4 2024

A detailed history of Oregon Public Employees Retirement Fund transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Oregon Public Employees Retirement Fund holds 12,681 shares of RCUS stock, worth $151,791. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,681
Previous 12,681 -0.0%
Holding current value
$151,791
Previous $193,000 2.59%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024
SELL
$13.69 - $18.01 $8,214 - $10,806
-600 Reduced 4.52%
12,681 $193,000
Q2 2024

Aug 01, 2024
SELL
$14.59 - $18.48 $17,508 - $22,176
-1,200 Reduced 8.29%
13,281 $202,000
Q1 2024

May 02, 2024
SELL
$14.83 - $20.18 $19,279 - $26,234
-1,300 Reduced 8.24%
14,481 $273,000
Q4 2023

Feb 12, 2024
SELL
$13.43 - $19.63 $1,705 - $2,493
-127 Reduced 0.8%
15,781 $301,000
Q3 2023

Oct 26, 2023
SELL
$17.62 - $23.54 $8,810 - $11,770
-500 Reduced 3.05%
15,908 $285,000
Q2 2023

Jul 26, 2023
SELL
$16.97 - $22.03 $6,788 - $8,812
-400 Reduced 2.38%
16,408 $333,000
Q1 2023

May 04, 2023
SELL
$15.96 - $23.15 $8,474 - $12,292
-531 Reduced 3.06%
16,808 $306,000
Q4 2022

Jan 26, 2023
BUY
$19.7 - $35.71 $1,536 - $2,785
78 Added 0.45%
17,339 $0
Q3 2022

Nov 01, 2022
BUY
$23.23 - $30.07 $45,554 - $58,967
1,961 Added 12.82%
17,261 $452,000
Q2 2022

Jul 25, 2022
BUY
$17.23 - $37.73 $263,619 - $577,269
15,300 New
15,300 $388,000

About Arcus Biosciences, Inc.

RCUS Quotes by TradingView
  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $864M
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Oregon Public Employees Retirement Fund Portfolio

Follow Oregon Public Employees Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oregon Public Employees Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on Oregon Public Employees Retirement Fund with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email